Resultados de la búsqueda 231-240 of 16572 for Biochemistry

  1. Hematología - Ensayos clínicos - Mayo Clinic

    Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

  2. Neurología - Ensayos clínicos - Mayo Clinic

    ... biochemical, electrophysiological and molecular properties. The study will also use skin fibroblasts as source of DNA to investigate for research purpose ...

  3. Neurología - Ensayos clínicos - Mayo Clinic

    ... biochemical, electrophysiological and molecular properties. The study will also use skin fibroblasts as source of DNA to investigate for research purpose ...

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to study the structure and biochemistry of the brain and/or bodily fluid and tissue after death. Comparison of specimens from ...

  5. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  6. Ensayos clínicos - Neurología

    The purpose of this study is to study the structure and biochemistry of the brain and/or bodily fluid and tissue after death. Comparison of specimens from ...

  7. Cirugía - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to determine the biomechanical, biochemical, and histological properties of human spinal cartilage, in both healthy and ...

  8. Cirugía - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to determine the biomechanical, biochemical, and histological properties of human spinal cartilage, in both healthy and ...

  9. Hematología - Ensayos clínicos - Mayo Clinic

    ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose optimization (Part ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic ...